Ivosidenib
Orphan DrugFDA Approved
Contents
Description
Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor used in the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation. While not directly indicated for classic neuroendocrine tumor of the appendix, IDH1 mutations can occur in various cancers, and ivosidenib may be explored in clinical trials if such a mutation is present.
Indications & Therapeutic Use
Acute Myeloid Leukemia (AML) with IDH1 mutation
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Buy / Source Ivosidenib — GNH India
16 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Ivosidenib products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Ivosidenib
| Generic Name | Ivosidenib |
| Brands | 1 brand available |
| Active Ingredient | Ivosidenib |
| Drug Class | Acute Myeloid Leukemia (AML) with IDH1 mutation |
| Manufacturer | Servier Pharmaceuticals |
| Dosage Forms | Tablets |
| Medical Code | L01XE30 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02074839 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes